Table 2. Efficacy of dupilumab.

Combination therapy refers to dupilumab plus topical corticosteroids.

SCORAD, Scoring Atopic Dermatitis; EASI, Eczema Area and Severity Index; Pruritus NRS, Pruritus Numeric Rating Scale; DLQI, Dermatology Life Quality Index; IGA, Investigator Global Assessment; EASI-50, 50% reduction in EASI score; EASI-75, 75% reduction in EASI score; SCORAD sleep VAS, Scoring Atopic Dermatitis sleep Visual Analogue Scale

Authors	Year	Efficacy
		Change in SCORAD (from baseline)	Change in EASI score	Change in Pruritus NRS score (from baseline)	Change in DLQI score (from baseline)	Patients achieving IGA score 0 or 1
Thaçi et al. [23]	2016	−56·9%	–73.7% (from Baseline)	−46·90%	−59·0%	33%
Beck et al. [24]	2014		Combination therapy EASI-50 = 100% (p < 0.05) Dupilumab monotherapy EASI-50 = 85% (p < 0.001) Combination therapy EASI-75 = 62% Dupilumab monotherapy EASI-75 = 62%	Dupilumab monotherapy = −55.7% Combination therapy = −70.7% (p < 0.05)		Dupilumab monotherapy = 40% (p < 0.001) Combination therapy = 52%
Blauvelt et al. [25]	2017	Combination therapy = −63·3% (p < 0·0001)	Combination therapy EASI-75 = 64% (p < 0·0001) and EASI-50 = 78% (p < 0·0001)	Combination therapy = −4·1 (p < 0·0001)	Combination therapy = –10.5 (p < 0.0001)	Combination therapy = 39% (p < 0·0001)
Guttman-Yassky et al. [26]	2019	−54.8% (p < 0.0001)	EASI-75 = 66.7% (p = 0·0001) and EASI-50 = 77.8% (p < 0·0001)	−51.5% (p = 0.0027)		37.0% (p = 0.0006)
Davis et al. [29]	2018		EASI-75 = 78.6% and EASI-50 = 92.9%			50%
Hamilton et al. [27]	2014		EASI-50 = 71.4%
Simpson et al. [28]	2016	SCORAD sleep VAS = –4.3 (p < 0.0001)		–3.2 (p < 0.0001)	–9.3 (p < 0.0001)
Blauvelt et al. [30]	2019		EASI-50 = 72.2% and EASI-75 = 53.6%	–4.46		44.30%